【SUNZEN 0148 交流专区】宏诚生科

icy97

BURSA MALAYSIA SECURITIES PUBLICLY REPRIMANDS AND/OR FINES SUNZEN BIOTECH BERHAD AND 2 EXECUTIVE DIRECTORS

SUNZEN BIOTECH BERHAD

Bursa Malaysia Securities Berhad  [200301033577 (635998-W)] (“Bursa Malaysia Securities”) has publicly reprimanded Sunzen Biotech Berhad (“SUNZEN” or “the Company”) and 2 of its executive directors, for breaches of the Bursa Malaysia Securities ACE Market Listing Requirements (“ACE LR”). In addition, the 2 executive directors of SUNZEN were imposed total fines of RM100,000.

SUNZEN was publicly reprimanded for breaching Rule 10.13(1)(b) read together with Rule 8.31(1) of the ACE LR for failing to obtain prior shareholders’ approval in respect of the diversification into a new business in the trading of crude palm oil and its derivative products such as palm kernel and palm kernel shell in February 2017 (“the Diversification”). SUNZEN had only announced the proposed ratification of the Diversification on 9 February 2018 and obtained its shareholders’ ratification of the Diversification on 30 May 2018.

The 2 executive directors of SUNZEN at the material time had breached Rule 16.13(b) of the ACE LR for permitting SUNZEN to commit the above breach and were imposed the following penalties:-  

No.	Name	Penalty
1.	Datuk Hong Choon Hau Managing Director cum Chief Executive Officer	Public reprimand and fine of RM50,000.00
2.	Lim Eng Chai Executive Director/Chief Operating Officer (resigned on 30 November 2018)	Public reprimand and fine of RM50,000.00

The finding of breach and imposition of the above penalties on SUNZEN and the directors were made pursuant to Rule 16.19 of the ACE LR upon completion of due process and after taking into consideration all facts and circumstances of the matter including the materiality/impact of the breach to SUNZEN and shareholders/investors and the roles, responsibilities, knowledge and conduct of the directors.

Bursa Malaysia Securities views the contravention seriously particularly as the requirement of Rule 10.13 of the ACE LR serves to protect the interest of shareholders and ensure shareholders are kept informed of all facts or information that might affect their interests.

Bursa Malaysia Securities has also reminded SUNZEN and its board of directors of their responsibility to maintain the appropriate standards of corporate responsibility and accountability to its shareholders and the investing public.

BACKGROUND

SUNZEN was principally engaged in biotechnology research and development and manufacturing and marketing of animal feed supplements and animal health care products, which includes feed additives, nutritional feed supplements, veterinary pharmaceutical and animal vaccines.  

The Company had commenced a new business in the trading of crude palm oil and its derivative products such as palm kernel and palm kernel shell (“CPO & Derivative Products Trading”) in February 2017. The Company had triggered Rule 10.13(1)(b) of the ACE LR where the CPO & Derivative Products Trading had contributed more than 25% of SUNZEN’s net profit as at the quarterly report for the financial period ended (“FPE”) 31 March 2017 (“QR 1/2017”), 30 June 2017 (“QR 2/2017”), 30 September 2017 (“QR 3/2017”) and 31 December 2017 (“QR 4/2017”) as follows:-

[td]

RM million Cumulative Results	Revenue from CPO & Derivative Products Trading	Total Revenue of SUNZEN	Net Profit from CPO & Derivative Products Trading	Total Net Profit of SUNZEN	Percentage contribution*
QR 1/2017	36.232	45.745	0.450	1.051	43%
QR 2/2017	103.557	121.621	2.706	2.578	105%
QR 3/2017	171.019	200.340	1.973	3.531	56%
QR 4/207	262.030	303.451	2.678	3.640	74%

* Percentage contribution of the net profit from CPO & Derivative Products Trading over the net profit of SUNZEN

SUNZEN and the executive directors had represented that:-

• the Diversification arose unintentionally out of the need to secure a consistent supply of refined, bleached and deodorized palm stearin (a derivative of crude palm oil) for the processing of powder fats, a feedstock for the manufacturing of the Group’s animal feed supplement; and

• the Company did not expect the CPO & Derivative Products Trading to be part of the Group’s business and did not foresee it would contribute significantly to the Group’s profitability/was sustainable as it was new/commenced only in February 2017 and the commodity market was unpredictable/volatile subject to price fluctuation.

However, the evidence showed that the Company had clearly intended to diversify into the CPO & Derivative Products Trading and both the Company and executive directors were aware of the material contribution of the CPO & Derivative Products Trading to the Company’s revenue, net profits and/or prospects as disclosed in the QR 1/2017, QR 2/1017, QR 3/2017 and QR 4/2017.  Further, the Company and executive directors had failed to make any proper assessment/analysis on the CPO & Derivative Products Trading vis-à-vis compliance with the ACE LR prior to the Diversification in February 2017.

The Company had only proceeded to obtain its shareholders’ ratification of the Diversification after the external auditors and company secretary highlighted the need to make an announcement and obtain shareholders’ approval of the Diversification during the Audit Committee meeting on 24 November 2017. Thereafter, the Company had appointed M&A Securities Sdn. Bhd. as the adviser on 5 December 2017, announced the proposed ratification of the Diversification on 9 February 2018, issued the circular to shareholders on 30 April 2018 and obtained the shareholders’ ratification of the Diversification on 30 May 2018.

Based on the roles, responsibilities, knowledge and/or involvement in the CPO & Derivative Products Trading of the executive directors, there were many instances (prior to and after the Diversification including in preparing and deliberation of the quarterly results) where the executive directors could and should be aware of the new business that the Company was venturing into and the potential/possible impact to the Company.  In addition, as the executive directors of the Company who were in charge of the day to day affairs of the Company including entrusted by the board to ensure compliance by the Company of relevant laws and rules, there was blatant failure/neglect by the executive directors in the discharge of their duties to identify, check, make proper assessment/analysis on the Diversification and ensure compliance of the ACE LR.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2019	31 Dec 2018	31 Dec 2019	31 Dec 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	44,302	74,444	239,864	296,160
2	Profit/(loss) before tax	-14,804	-7,878	-20,557	-6,958
3	Profit/(loss) for the period	-14,275	-7,825	-19,156	-6,937
4	Profit/(loss) attributable to ordinary equity holders of the parent	-12,773	-7,916	-17,460	-6,939
5	Basic earnings/(loss) per share (Subunit)	-2.42	-1.57	-3.31	-1.37
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1700		0.2000

icy97

icy97 发表于 22-7-2019 05:04 AM
http://www.bursamalaysia.com/market/listed-companies/company-announcements/6213145

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) RELATED PARTY TRANSACTIONS
Description	SUNZEN BIOTECH BERHAD ("Sunzen" or "the Company")-        Settlement Agreement and Disposal of Shares in Amplio Ingredients Sdn. Bhd. ("Settlement")
Unless stated otherwise, the terms used herein shall carry the same meaning as those defined in the announcement dated 4 July 2019 in relation to the above Settlement. Reference is made to the announcements dated 4 July 2019 and 9 July 2019. The Board of Directors of Sunzen wishes to announce that the Company has received in full from the Purchaser the purchase consideration for the Sale Shares on 11 March 2020 and accordingly, the Sale Shares is completed. This announcement is dated 12 March 2020.

icy97

SUNZEN BIOTECH BERHAD

Particulars of substantial Securities Holder

Name	DATUK HONG CHOON HAU
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary Shares

Details of changes

No	Date of change	No of securities	Type of Transaction	Nature of Interest
1	17 Apr 2020	66,700,950	Disposed	Direct Interest
	Name of registered holder	Maybank Securities Nominees (Tempatan) S/B Maybank Kim Eng Securities Pte Ltd for Maybank Pte Ltd
	Address of registered holder	Level 5 MaybanLife Tower Dataran Maybank 1 Jalan Maarof 59000 Kuala Lumpur
	Description of "Others" Type of Transaction

Circumstances by reason of which change has occurred	Disposal of Shares
Nature of interest	Direct Interest
Direct (units)	83,298,885
Direct (%)	15.75
Indirect/deemed interest (units)	220,800
Indirect/deemed interest (%)	0.04
Total no of securities after change	83,519,685
Date of notice	20 Apr 2020
Date notice received by Listed Issuer	20 Apr 2020

icy97

Notice of Interest Sub. S-hldr (Section 137 of CA 2016)

Amended Announcements
Please refer to the earlier announcement reference number: CS1-15042020-00001

SUNZEN BIOTECH BERHAD

Particulars of Substantial Securities Holder

Name	MR TEO YEK MING
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary Shares
Name & address of registered holder	(1) Teo Yek MingNo. 196, Batu 5, Tanjung Gading, 84000 Ledang, Johor, Malaysia.(Direct Interest - 68,632,050 Ordinary Shares)(2) Maybank Nominees (Tempatan) Sdn. Bhd. pledged securities account for Teo Yek MingNo. 57-1 & 57-2, Jalan Sulaiman, 84000 Muar, Johor, Malaysia.(Direct Interest - 28,200 Ordinary Shares)(3) Finsource Capital Sdn. Bhd.Unit 30-03, Level 30, Tower B, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200, Kuala Lumpur, W.P. Kuala Lumpur, Malaysia. (Indirect Interest - 740,600 Ordinary Shares)(4) Lim Choon LongNo. 196, Batu 5, Tanjung Gading, 84000 Ledang, Johor, Malaysia.(Indirect Interest - 126,000 Ordinary Shares)

Date interest acquired & no of securities acquired
Date interest acquired	17 Apr 2020
No of securities	66,700,950
Circumstances by reason of which Securities Holder has interest	Acquisition of Shares
Nature of interest	Direct and Indirect Interest
Total no of securities after change
Direct (units)	68,660,250
Direct (%)	12.99
Indirect/deemed interest (units)	866,600
Indirect/deemed interest (%)	0.164
Date of notice	20 Apr 2020
Date notice received by Listed Issuer	20 Apr 2020

icy97

SUNZEN BIOTECH BERHAD

Date of change	16 Jun 2020
Name	DATUK HONG CHOON HAU
Age	44
Gender	Male
Nationality	Malaysia
Designation	Group Managing Director
Directorate	Executive
Type of change	Resignation
Reason	Pursue personal interest

Date of change	16 Jun 2020
Name	MR TEO YEK MING
Age	36
Gender	Male
Nationality	Malaysia
Designation	Group Managing Director
Directorate	Executive
Type of change	Appointment

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Others	Malaysian Certificate of Education (SPM)	Sekolah Menengah Kebangsaan Parit Bunga

Working experience and occupation	Mr Teo Yek Ming is an entrepreneur and savvy investor who has more than ten (10) years of combined experience in managing businesses of various industries including aquaculture, information technology, furniture, and property investment.After completing his high school education, he started his career as a sales and marketing executive for a hardware trading company. Subsequently, he ventured into his first business in 2006, The Ring Telecommunication, which was a company involved in the retail of mobile phones. In 2012, he established Phoenix Arowana Breeders Sdn. Bhd., an aquaculture company involved in arowana fish farming, marketing and distribution. Mr Teo later set up Avex Consulting Sdn. Bhd. and Avex Technology Sdn. Bhd. in 2016, which are principally involved in the software development for local businesses. In 2017, he has become one of the major shareholders of Goodnight Sdn. Bhd. (Goodnight), a leading bedding manufacturer in Malaysia. He is currently the managing director of Goodnight overseeing the overall operation of the Goodnight group businesses. He has been actively involved in the execution of business expansion plan through incorporation and acquisition of some upstream and downstream outfits in diversifying the Goodnight group businesses to include foam manufacturing, sofa manufacturing, office furniture trading, sales, hire purchase and factory outlets.
Directorships in public companies and listed issuers (if any)	Nil
Family relationship with any director and/or major shareholder of the listed issuer	Nil
Any conflict of interests that he/she has with the listed issuer	Nil
Details of any interest in the securities of the listed issuer or its subsidiaries	Details of interest held in Sunzen Biotech Berhad:-Ordinary SharesDirect - 69,160,250Indirect - 126,000Warrants 2016/2021Direct - 25,870,700Indirect - Nil

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2020	31 Mar 2019	31 Mar 2020	31 Mar 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	21,341	66,912	21,341	66,912
2	Profit/(loss) before tax	-3,186	-1,070	-3,186	-1,070
3	Profit/(loss) for the period	-3,005	-943	-3,005	-943
4	Profit/(loss) attributable to ordinary equity holders of the parent	-2,568	-961	-2,568	-961
5	Basic earnings/(loss) per share (Subunit)	-0.49	-0.19	-0.49	-0.19
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1700		0.1700

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2020	30 Jun 2019	30 Jun 2020	30 Jun 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	12,679	69,716	34,020	136,628
2	Profit/(loss) before tax	-1,824	-1,506	-5,010	-2,576
3	Profit/(loss) for the period	-1,870	-1,552	-4,875	-2,495
4	Profit/(loss) attributable to ordinary equity holders of the parent	-1,696	-1,303	-4,264	-2,264
5	Basic earnings/(loss) per share (Subunit)	-0.32	-0.25	-0.81	-0.43
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1600		0.1700

icy97

SUNZEN BIOTECH BERHAD

Date of change	01 Oct 2020
Name	MR CHING CHEE PUN
Age	48
Gender	Male
Nationality	Malaysia
Type of change	Redesignation
Previous Position	Non-Independent Director
New Position	Executive Director
Directorate	Executive

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SUNZEN BIOTECH BERHAD ("SUNZEN" OR "THE COMPANY")- DISPOSAL OF PROPERTY
The Board of Directors of Sunzen wishes to announce that the Company had on 11 November 2020 entered into a Sale and Purchase Agreement (“SPA”) with Ingredients Plus Properties Sdn. Bhd. [Registration No. 202001031368 (1387688-P)] of No. 8, Jalan Sungai Kayu Ara 32/31, Taman Perusahaan Berjaya, 40460 Shah Alam, Selangor Darul Ehsan, to sell a piece of  freehold industrial land held under individual title GRN 99189, Lot No. 69279, Mukim Klang Daerah Klang, Negeri Selangor measuring approximately 4,047 square metres and a three storey factory building erected thereon bearing postal address of No. 50, Jalan Anggerik Mokara 31/47, Kota Kemuning 40460 Shah Alam, Selangor Darul Ehsan together with the furniture, fixtures and fittings, storage steel racking and all other things as listed in the SPA (hereinafter be referred to as “the Disposal”) for a total cash consideration of RM14,200,000 subject to the terms and conditions as set out in the SPA. Please refer to the attachment for further details of the Disposal. This announcement is dated 11 November 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3104176

Attachments Announcement - Disposal of Property.pdf

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2020	30 Sep 2019	30 Sep 2020	30 Sep 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	20,358	62,047	54,378	195,562
2	Profit/(loss) before tax	131	-3,170	-4,879	-5,753
3	Profit/(loss) for the period	53	-4,064	-4,822	-4,881
4	Profit/(loss) attributable to ordinary equity holders of the parent	-383	-4,099	-4,647	-4,687
5	Basic earnings/(loss) per share (Subunit)	-0.07	-0.78	-0.88	-0.89
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1600		0.1700

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) RELATED PARTY TRANSACTIONS
Description	SUNZEN BIOTECH BERHAD ("SUNZEN" OR THE "COMPANY")(I) PROPOSED ACQUISITION; AND(II) PROPOSED DIVERSIFICATION
On behalf of the board of directors of SUNZEN, M&A Securities Sdn Bhd wishes to announce that on 12 January 2021, SUNZEN had entered into a conditional share sale agreement with Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap (collectively, the “Vendors”) for the proposed acquisition of 100% of the issued share capital in FSSB, for a purchase price of RM6,800,000 (“Proposed Acquisition”) to be satisfied by the allotment and issuance of 41,212,121 new ordinary shares in SUNZEN (“SUNZEN Shares”) at an issue price of RM0.165 per SUNZEN Share. In conjunction with the Proposed Acquisition, the Company intends to undertake the proposed diversification of the business activities of SUNZEN and its subsidiaries to include money lending (“Proposed Diversification”). (The Proposed Acquisition and Proposed Diversification are collectively referred to as the “Proposals”). Kindly refer to the attachment on further details of the Proposals. This announcement is dated 12 January 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3120701

Attachments 120121 - Acqusition announcement.pdf

Notice of Person Ceasing (Section 139 of CA 2016)

SUNZEN BIOTECH BERHAD

Particulars of Substantial Securities Holder

Name	DATUK HONG CHOON HAU
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary Shares
Name of registered holder	Maybank Securities Nominees (Tempatan) S/B & UOB Kay Hian Nominees (Tempatan) S/B
Date of cessation	13 Jan 2021

No of securities disposed	80,091,185
Circumstances by reason of which a person ceases to be a substantial shareholder	Disposal of Shares
Nature of interest	Direct Interest
Date of notice	15 Jan 2021
Date notice received by Listed Issuer	15 Jan 2021

Notice of Interest Sub. S-hldr (Section 137 of CA 2016)

SUNZEN BIOTECH BERHAD

Particulars of Substantial Securities Holder

Name	MADAM CHEN KIM LIAN
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary Shares
Name of registered holder	CHEN KIM LIAN

Date interest acquired & no of securities acquired
Date interest acquired	13 Jan 2021
No of securities	66,700,950
Circumstances by reason of which Securities Holder has interest	Acquisition of Shares
Nature of interest	Direct Interest
Total no of securities after change
Direct (units)	66,700,950
Direct (%)	12.6
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Date of notice	15 Jan 2021
Date notice received by Listed Issuer	15 Jan 2021

Expiry/Maturity of the securities

SUNZEN BIOTECH BERHAD

Instrument Category	Securities of PLC
Instrument Type	Warrants
Type Of Expiry	Expiry/Maturity of the securities
Mode of Satisfaction of Exercise/Conversion price	Cash
Exercise/ Strike/ Conversion Price	Malaysian Ringgit (MYR) 0.2500
Exercise/ Conversion Ratio	1:1
Settlement Type / Convertible into	Physical (Shares)
Last Date & Time of Trading	08 Feb 2021 05:00 PM
Date & Time of Suspension	09 Feb 2021 09:00 AM
Last Date & Time for Transfer into Depositor's CDS a/c	18 Feb 2021 04:30 PM
Date & Time of Expiry	25 Feb 2021 05:00 PM
Date & Time for Delisting	26 Feb 2021 09:00 AM

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3122944

Attachments Notice to Warrantholders - Expiry of Warrants 2016-2021.pdf

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	SUNZEN BIOTECH BERHAD ("SUNZEN" OR "COMPANY") PROPOSED PRIVATE PLACEMENT OF UP TO 20% OF THE TOTAL NUMBER OF ISSUED SHARES IN SUNZEN
On behalf of the Board of Directors of SUNZEN, M&A Securities Sdn Bhd wishes to announce that the Company proposes to undertake a private placement of up to 20% of the total number of issued shares (“Proposed Private Placement”). The Proposed Private Placement will be undertaken in accordance with the general mandate pursuant to Sections 75 and 76 of the Companies Act 2016 obtained from the shareholders of the Company at the Annual General Meeting convened on 29 June 2021, whereby the Company is seeking for authority to be given to allot and issue new ordinary shares not exceeding 20% of the total number of issued SUNZEN shares ("Shareholders’ Mandate"). The Shareholders’ Mandate may be utilised until 31 December 2021, after which the 10% limit under Rule 6.04(1) of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad will be reinstated. Further details of the Proposed Private Placement are set out in the attachment below. This announcement is dated 27 September 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3195689

Attachments 270921 - Private Placement.pdf

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	SUNZEN BIOTECH BERHAD ("SUNZEN" OR "COMPANY") PROPOSED PRIVATE PLACEMENT OF UP TO 20% OF THE TOTAL NUMBER OF ISSUED SHARES IN SUNZEN
Reference is made to the announcement dated 27 September 2021 in relation to the Proposed Private Placement (“Announcement”). With reference to the Announcement, certain sections of the Announcement has been clarified and amended as underlined. Further information is disclosed in the attachment herein. This announcement is dated 29 October 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3205483

Attachments 291021 - Additional Annct.pdf

icy97

SUNZEN BIOTECH BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	PRIVATE PLACEMENT OF UP TO 20% OF THE TOTAL NUMBER OF ISSUED SHARES IN SUNZEN
No. of shares issued under this corporate proposal	31,000,000
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.1750
Par Value($$) (if applicable)	Malaysian Ringgit (MYR)   0.000
Latest issued share capital after the above corporate proposal in the following
Units	611,092,859
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 89,643,846.630
Listing Date	23 Nov 2021

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2021

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2021	30 Sep 2020	30 Sep 2021	30 Sep 2020
		$$'000	$$'000	$$'000	$$'000

1	Revenue	17,445	20,358	61,449	54,378
2	Profit/(loss) before tax	520	131	1,635	-4,879
3	Profit/(loss) for the period	158	53	808	-4,822
4	Profit/(loss) attributable to ordinary equity holders of the parent	71	-383	31	-4,647
5	Basic earnings/(loss) per share (Subunit)	0.01	-0.07	0.01	-0.88
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1700		0.1700

icy97

SUNZEN BIOTECH BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Others
Details of corporate proposal	Share Issuance Scheme
No. of shares issued under this corporate proposal	14,330,000
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.1395
Par Value($$) (if applicable)
Latest issued share capital after the above corporate proposal in the following
Units	625,422,859
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 92,984,169.630
Listing Date	30 Nov 2021

icy97

SUNZEN BIOTECH BERHAD

Particulars of substantial Securities Holder

Name	MR TEO YEK MING
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary Shares

Details of changes

No	Date of change	No of securities	Type of Transaction	Nature of Interest
1	25 Nov 2021	14,330,000	Others	Direct Interest
	Name of registered holder	RHB Nominees (Tempatan) Sdn. Bhd. pledged securities account for Teo Yek Ming
	Description of "Others" Type of Transaction	Exercise of Options

Circumstances by reason of which change has occurred	Exercise of Options under the Share Issuance Scheme
Nature of interest	Direct Interest
Direct (units)	98,510,417
Direct (%)	15.91
Indirect/deemed interest (units)	11,035,091
Indirect/deemed interest (%)	1.78
Total no of securities after change	109,545,508
Date of notice	29 Nov 2021
Date notice received by Listed Issuer	29 Nov 2021

icy97

Profile for Securities of PLC

SUNZEN BIOTECH BERHAD

Instrument Category	Securities of PLC
Instrument Type	Warrants
Description	Bonus issue of 356,894,609 warrants of Sunzen Biotech Berhad ("Sunzen") ("Warrants") on the basis of 1 Warrant for every 2 existing ordinary shares in Sunzen held as 5.00 p.m. on 8 September 2022 ("Entilement Date") ("Bonus Issue of Warrants")

Listing Date	21 Sep 2022
Issue Date	14 Sep 2022
Issue/ Ask Price	Not Applicable
Issue Size Indicator	Unit
Issue Size in Unit	356,894,609
Maturity	Mandatory
Maturity Date	13 Sep 2027
Revised Maturity Date
Name of Guarantor	Not Applicable
Name of Trustee	Not Applicable
Coupon/Profit/Interest/Payment Rate	Not Applicable
Coupon/Profit/Interest/Payment Frequency	Not Applicable
Redemption	Not Applicable
Exercise/Conversion Period	5.00   Year(s)
Revised Exercise/Conversion Period	Not Applicable
Exercise/Strike/Conversion Price	Malaysian Ringgit (MYR)   0.2000
Revised Exercise/Strike/Conversion Price	Not Applicable
Exercise/Conversion Ratio	1:1
Revised Exercise/Conversion Ratio	Not Applicable
Mode of satisfaction of Exercise/ Conversion price	Cash
Settlement Type/ Convertible into	Physical (Shares)

icy97

Type	Announcement
Subject	OTHERS
Description	SUNZEN BIOTECH BERHAD-        CESSATION OF BUSINESS OPERATIONS FOR ANIMAL HEALTH DIVISION
Sunzen Biotech Berhad (“Sunzen” or “Company”) wishes to announce that as part of the Company’s business strategy transformation aimed at revitalising the financial performance of the Company, the Company will commence the process of cessation of business operations of Animal Health (“AH”) division in order to reduce the financial expenditures and strengthen the financial performance of the Company. The AH division has been continuously incurring losses for the past financial years amidst the challenging business environment which has strained the overall financial condition of the Company despite concerted efforts of the management team to overcome the challenging business environment for the animal health industry. A summary of the audited financial performance of the AH division for the past 5 financial years ended 31 December is appended herewith for information: 2018 2019 2020 2021 2022 Revenue (RM'000) 15,303 11,954 16,462 12,048 5,838 Revenue contribution to the Group on consolidated basis (%) 5.09 4.97 20.02 13.32 6.01 Loss before taxation (RM'000) 7,489 14,241 13,478 3,082 4,672 Going forward, the Company would focus its resources on the existing business in human health and loan financing of which had respectively contributed 84.19% and 9.80% for the total revenue of the Company for the financial year ended 31 December 2022. The Company and its Board of Directors are of the view that AH division is no longer commercially sustainable and consider that the cessation of the business operations of AH division is in the best interest of the Company and the shareholders as a whole. The cessation of operations of AH division will not have any material effect on the operations and financial performance of the Company for the financial year ending 30 June 2024. This announcement is dated 8 April 2024.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2024

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		Three Months	Three Months	Eighteen Months	Eighteen Months
		01 Apr 2024 To	01 Apr 2023 To	01 Jan 2023 To	01 Jan 2022 To
		30 Jun 2024	30 Jun 2023	30 Jun 2024	30 Jun 2023
		$$'000	$$'000	$$'000	$$'000

1	Revenue	20,611	0	142,699	0
2	Profit/(loss) before tax	841	0	15,686	0
3	Profit/(loss) for the period	244	0	10,435	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	403	0	9,172	0
5	Basic earnings/(loss) per share (Subunit)	0.06	0.00	1.30	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2000		0.1700

icy97

Type	Announcement
Subject	OTHERS
Description	- REVALUATION OF NON-CURRENT ASSETS
In accordance with Rule 9.19(46) of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors (“Board”) of Sunzen Biotech Berhad (“Sunzen” or “Company”) wishes to inform that the Board of Sunzen had on 28 August 2024 approved the valuation report for the properties held by its subsidiaries and the incorporation of the revaluation surplus of RM9,868,610 into the Group’s unaudited financial results on consolidated results for the financial quarter ended 30 June 2024. Please refer to the attachment for the details of the announcement. This announcement is dated 29 August 2024.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3479222

Attachments Revaluation of Non-Current Assets.pdf

icy97

SUNZEN BIOTECH BERHAD

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-23092024-00001
Subject	Article Entitled: "Sunzen Biotech aims to sell assets"
Description	SUNZEN BIOTECH BERHAD ("SUNZEN" OR "THE COMPANY)Article Entitled: "Sunzen Biotech aims to sell assets"
Query Letter Contents	We refer to the above media article appearing in NewStraitsTimes dated 23 September 2024, a copy of which is enclosed for your reference. In particular, we would like to draw your attention to the underlined sentence which is reproduced as follows :- "Sunzen Biotech Bhd plans to divest its land and factory in Kota Kemuning, Shah Alam, Selangor, with a market value estimated between RM16million and RM18million." In accordance with Bursa Securities' Corporate Disclosure Policy, kindly furnish Bursa Securities with an announcement for public release confirming or denying the above reported article in particular the underlined sentences after due and diligent enquiry with all the directors, major shareholders and all such other person reasonably familiar with the matters about which the disclosure is to made in this respect. In the event you deny the above reported sentences or any other part of the article, you are required to set forth facts sufficient to support the same.
Clarification on the Article Published in The New Straits Times on 23 September 2024With reference to the article titled "Sunzen Biotech Aims to Sell Assets" published in The New Straits Times on 23 September 2024 (the "Article"), specifically regarding the statement:“Sunzen Biotech Bhd plans to divest its land and factory in Kota Kemuning, Shah Alam, Selangor, with a market value estimated between RM16 million and RM18 million.”The Board of Directors of Sunzen Biotech Berhad ("the Board") has conducted a thorough inquiry involving all directors, major shareholders, and management regarding recent media inquiries dated 20 September 2024. The Board wish to clarify that while the management referenced the matter during these press inquiries, this was in the context of an initial study and planning phase related to the cessation of our animal health division, which the Company has previously announced on 8 April 2024.It is important to note that the discussions are still exploratory and have not yet been presented to the Board for further consideration. Additionally, the valuation amount mentioned in the article is based on a recent valuation conducted by the Sunzen Group’s properties, which was announced on 29 August 2024.Once the feasibility study is finalised and the Board’s approval is obtained, the Company will make the necessary announcements to Bursa Malaysia Securities Berhad.This announcement is dated 24 September 2024.